spacer
home > ebr > current issue
PUBLICATIONS

European Biopharmaceutical Review

ebr
Autumn 2020

   
Text
PDF
bullet
In Brief
Boston Diary – Day 144

144 days after COVID-19 hit his hometown of Boston, EBR’s industry advisor, Emile Bellot, reflects on all that has changed, and whether the world will ever be the same again.
 
view
download pdf
bullet
Features
Changing Perceptions

Aras Azadian of Avicanna

The medicinal benefits of cannabis are quickly becoming undeniable in this new climate. Aras Azadian, CEO of Avicanna, speaks to EBR about the remaining stigma and the potential benefits of cannabinoids.
 
view
download pdf
The Numerous Challenges of a Rapidly Developing Sector

Carl Niedbala at Founder Shield

Now, more than ever, the biotech industry faces a significant number of risks, including a lengthy pipeline, the complicated process of gaining FDA approval, and higher healthcare costs.
 
view
download pdf
Neoantigens: IP Considerations for an Emerging Class of Cancer Immunotherapy

Fran Salisbury and Ine Vanderleyden at Mewburn Ellis

Previously, cancer treatments took a ‘one-size-fits-all’ approach’; however, new personalised clinical technologies are being developed that can incite a patient’s immune system to destroy cancer cells in the body.
 
view
download pdf
Mesenchymal Stem Cells: The Next Generation of Pain Treatments

Leo Lee at Regeneus

Pain has always been, and remains, a major burden for patients, stemming from a variety of diseases. Regenerative treatments, such as stem cell treatments using mesenchymal stem cells, may be able to help carry that burden.


 
view
download pdf
bullet
rare diseases
A Conversation About Systemic Sclerosis

Dr Alexandre Akoulitchev and Dr Ewan Hunter, the Chief Scientific Officer and Chief Data Officer of Oxford BioDynamics, respectively, discuss with EBR the R&D and treatment options available for systemic sclerosis.


 
view
download pdf
The Importance of Patient Advocacy

Jennifer McGrain at Zambon shares her views with EBR surrounding the vital role patient advocates have in helping patients deal with their conditions, particularly those suffering from rare diseases who may struggle to find vital support.

 
view
download pdf
bullet
Gene editing and CRISPR
Novel Approaches to Overcome CRISPR In Vitro Delivery Challenges

Dr Paul Monnier at Cytosurge

Although CRISPR is widely used in research laboratories, many challenges regarding delivery and safety remain to be overcome for both in vivo and in vitro applications.

 
 
view
download pdf
Choosing the Right CRISPR Tools to Generate Your Genetically Modified Mice

James Chon at GenScript

Genetically modified mice are a vital part of life science research, however, the prolonged, financially burdensome process may be changing.
 
view
download pdf
How Gene Editing May Pave the Way for Personalised Medicine

Rolf Turk at Integrated DNA Technologies

In the eight years since the seminal paper on CRISPRCas9 gene editing was published, the technology has presented with a huge amount of potential for bringing novel therapies to patients suffering from single gene mutation diseases.
 
view
download pdf
The Solution to Complex CRISPR Modifications: Droplet Digital PCR

Dr Karen McAulay, Zara Puckrin, and Dr Robert Annand at REPROCELL

Steps must be taken to ensure the scientific and commercial viability of the CRISPR-Cas9 system if the technology is to reach its full potential.

 
view
download pdf
bullet
Antimicrobial resistance
Treatment Options for Clostridioides Difficile

Shelley McLendon and Kelley Struble at ICON

The increase of hospitalisations, caused by COVID-19, has also seen an uptick in the spread of antimicrobial diseases such as C diff: now an urgent antibiotic resistance threat.
 
view
download pdf
The Other – Silent – Pandemic

Philippe Villain-Guillot at Nosopharm

Antibiotic resistance is a severe threat to world health, one that is exacerbated by the pharmaceutical industry’s ageing antibiotic arsenal that has yet to be sufficiently renewed.

 
view
download pdf
Another Crisis Is Brewing

Regina Au at BioMarketing Insight USA

The costly and time-consuming models for drug development must change in order for pharma companies to produce new antibiotics and effectively combat antimicrobial resistance.
 
view
download pdf
bullet
Biopharma post-COVID-19
How Pharma Can Conquer the Next Pandemic

Vladimir Tkachenko at Amaxa Pharma

Months into the pandemic, it’s worth taking a look at what measures have been taken, and what lessons have been learned by the pharma industry, to ensure it will be ready for the next pandemic – whenever it should occur.

 
view
download pdf
Fluidity One-W Serum

Accurately characterising the immune response against SARSCoV- 2 is vital in managing the current COVID-19 pandemic; Fluidity One-W Serum could be the solution in the development of reliable antibody tests.

 
view
download pdf
Medical Communications Transformed

Shairose Ebrahim at integrated medhealth communication (imc)

COVID-19 has led to the drastic transformation of many professional sectors, including those in the medical community. The medical communications sector has been instrumental in making these transformations as smooth as possible.
 
view
download pdf
   
spacer


Published quarterly in
January, April,
July, and October

News and Press Releases

Merck Launches ADC ExpressTM Services to Accelerate Pre-clinical Conjugation Candidate Selection

• Provides rapid production of antibody drug conjugates (ADCs) for best candidate selection • Established platform technology to reliably scale target molecules • Reduces time to clinic through comprehensive ADC services from pre-clinical to commercial from a single source
More info >>

White Papers

Comparator Sourcing in Oncology Trials

Clinical Services International

This is an exciting time for oncology trials, year on year record numbers of therapeutics are launched and the indications for many drugs on the market are increasing rapidly. Immunotherapies and next generation biotherapeutics are being approved for more tumour types and a growing percentage of the late stage oncology pipeline are targeted biologics.
More info >>

Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement